ஐரோப்பிய சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஐரோப்பிய சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஐரோப்பிய சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் Today - Breaking & Trending Today

Galderma: Alluzience, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Data supporting the positive decision demonstrated that patients treated with Alluzience for wrinkles had a rapid onset of effect starting from day one, with improvements lasting up to six months.1 Galderma ....

Czech Republic , Kostenloser Wertpapierhandel , Joanna Czuwara , Lauren Starr , Justine Brodie , Head Of Franchise Communications At Galderma , Department Of Dermatology , Warsaw Medical University , Associate Professor , European Marketing Authorization Application , Alexandre Brennan Head , Global Business Unit , Consumer Care , Placebo Controlled Study , Single Treatment , Ready To Use Toxin , Moderate To Severe Glabellar , Aesthet Surg , Franchise Communications , Senior Account Manager , செக் குடியரசு , லாரன் நட்சத்திரம் , துறை ஆஃப் தோல் நோய் , வார்சா மருத்துவ பல்கலைக்கழகம் , இணை ப்ரொஃபெஸர் , ஐரோப்பிய சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் ,

MorphoSys AG Reports First Quarter 2021 Results

MorphoSys AG Reports First Quarter 2021 Results
ACCESSWIRE
06 May 2021, 06:43 GMT+10
Cost of Sales: In the first three months of 2021, cost of sales increased to € 5.0 million (3M 2020: € 3.3 million).
Research and Development (R&D) Expenses: In the first three months of 2021, research and development expenses were € 33.3 million (3M 2020: € 21.5 million). Growth over 2020 reflects the increased investment to support the advancement of proprietary programs and consisted primarily of expenses for external laboratory services and personnel expenses.
Selling, General and Administrative (SG&A) Expenses: Selling expenses increased in the first three months of 2021 to € 28.2 million (3M 2020: € 12.8 million) and general and administrative expenses remained almost unchanged at € 10.3 million (3M 2020:€ 10.1 million). The year-over-year increase in selling expenses was primarily driven by the full quarter impact of the expenses for services provided by ....

United States , United Kingdom , Janssen Biotech Inc , Xencor Inc , Drug Administration , Janssen Research Development , Morphosys Us Inc , Morphosys Group Key Figures , Development Rd Expenses , European Medicines Agency , Net Loss , Operational Outlook , European Marketing Authorization Application , Sys Group Key Figures , Janssen Research , Janssen Biotech , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஜான்சன் பயோடெக் இன்க் , ஜான்சன் ஆராய்ச்சி வளர்ச்சி , வளர்ச்சி ர்ட் செலவுகள் , நிகர இழப்பு , செயல்பாட்டு ஔட்‌லுக் , ஐரோப்பிய சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் , ஸிஸ் குழு விசை புள்ளிவிவரங்கள் , ஜான்சன் ஆராய்ச்சி ,

MorphoSys AG Reports First Quarter 2021 Results

MorphoSys AG Reports First Quarter 2021 Results
Tremfya royalties of € 11.6 million
Reaffirming group revenue guidance of € 150 to € 200 million
Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST
(1:00pm BST/8:00am EDT)
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) reports financial results for the first quarter of 2021.
For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline, said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. While we experienced headwinds from the pandemic in the first quarter, we are cautiously optimistic that the COVID-19 impact in the U.S. will start to diminish in the second half of 2021. We are confident in the potential of Monjuvi given its broad second-line label and overall profile in the r/r DLBCL setting ....

United States , United Kingdom , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Myles Clouston , Jeanette Bressi , Janssen Biotech Inc , Xencor Inc , Drug Administration , Janssen Research Development , Morphosys Us Inc , Group Revenues , Exchange Commission , Us Communications , Morphosys Group Key Figures , Development Rd Expenses , European Medicines Agency , Health Canada , Swiss Agency For Therapeutic Products Swissmedic , Chief Executive Officer , Swiss Agency , Therapeutic Products , New Drug Submission , Sung Lee , Chief Financial Officer ,